Chronic activation of the renin–angiotensin–aldosterone system (RAAS) plays a key role in
the development of hypertension, and cardiac and renal diseases. RAAS inhibitors, such as …

Combination therapy is necessary for most patients with hypertension, and agents that
inhibit the renin-angiotensin-aldosterone system (RAAS) are mainstays in hypertension …

J Clin Hypertens (Greenwich). 2011; 13: 506–516.© 2011 Wiley Periodicals, Inc.
Combinations of the direct renin inhibitor aliskiren with angiotensin receptor blockers (ARBs) …

Inhibition of the renin-angiotensin-aldosterone system (RAAS) improves clinical outcomes in
patients with hypertension, chronic kidney disease (CKD), and heart failure. Initially, a …

Background: Renin–angiotensin system (RAS) blockade with ACE inhibitor and/or
angiotensin receptor blocker therapy can lead to increased potassium levels, hence the …

AIMS: This article reviews the importance of the renin–angiotensin–aldosterone system
(RAAS) in the cardiometabolic continuum; presents the pros and cons of dual RAAS …

Combining an angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II receptor
blocker (ARB) lowers blood pressure (BP) by 4/3 mmHg compared to either agent alone …

Background The aim of this study was to assess dual renin system intervention with the
maximum recommended doses of aliskiren and valsartan, compared with each drug alone …

Importance of the field: The renin-angiotensin-aldosterone system (RAAS) is a key regulator
of blood pressure (BP), as well as volume and electrolytes, in both hypertensive and …

The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathophysiology
of arterial hypertension as well as in more complex mechanisms of cardiovascular and renal …